3 ASX healthcare stocks surging after strong FY24 earnings

These ASX healthcare stocks all came in with solid numbers in FY24.

| More on:
Three health professionals at a hospital smile for the camera.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX healthcare stocks are buzzing with activity as several key players report their FY24 earnings.

Among them, Clarity Pharmaceuticals Ltd (ASX: CU6), Polynovo Ltd (ASX: PNV), and Mayne Pharma Group Ltd (ASX: MYX) have delivered sound results, and the market has reacted swiftly.

Let's dive straight into it.

ASX healthcare stocks surge

Clarity Pharmaceuticals had a notable year. Investors have bid the ASX healthcare stock nearly 4% higher at $7.15 after its FY24 results today.

The company reported a 49% increase in revenue, reaching $2.77 million for FY24.

However, the loss from ordinary activities after tax widened by 72% to $42.3 million. Despite the increased losses, Clarity advanced its clinical development programs and says it strengthened its supply chain.

The company successfully completed a capital raising of $121 million in April 2024, bolstering its cash reserves.

These progressions continue its growth in the radiopharmaceuticals space. The directors' report commented positively on the results:

The achievements made in the last financial year position Clarity Pharmaceuticals as a leader in the
radiopharmaceuticals space, with a strong competitive advantage.

The Group's strategy is to first launch its Targeted Copper Theranostic (TCT) products for approval in the United States, the largest oncology market in the world, with five open Investigational New Drug (IND) applications with the US Food and Drug Administration (FDA),

Polynovo shows strong results

Polynovo also delivered solid FY24 results, with revenue surging 57.5% year over year to $104.8 million.

The ASX healthcare stock noted "record monthly sales" of $9.2 million and $9.8 million in April and May of this year, respectively.

Growth was particularly strong in the United States market, where sales jumped 49% year over year. Polynovo has been expanding its market presence there, increasing its US customer accounts by 197 over the year.

This growth translated into a net profit of $5.3 million, a significant turnaround from the previous year's net loss of a similar amount.

The company also launched a full market campaign for its NovoSorb MTX product during the period.

Polynovo chairman David Williams highlighted the company's global reach:

One step at a time, we are servicing the world. However, we remain continually surprised by where surgeons would like to use our products.

Mayne Pharma rockets 14%

Last but not least, we have Mayne Pharma. Investors appear delighted with Mayne Pharma shares today, sending them 13.7% higher to $4.48 at the time of writing.

The ASX healthcare stock showed a marked improvement in its financial performance for FY24. Firstly, revenues were up 112% year over year to $388 million.

Gross profit was also up 162% year over year, leading to a $23 million in pre-tax profit. This is a growth of $118 million in earnings from the previous year.

The turnaround is driven by its broadened portfolio in Dermatology and Women's Health, which leverages its existing commercial infrastructure.

Its Women's Health business grew 131% over the year, printing $143 million at the top line, underscored by sales of its NEXTSTELLIS label.

Mayne Pharma CEO Shawn Patrick O'Brien noted:

Looking ahead, we are focused on capitalising on our market leading position in Women's Health and Dermatology to drive further revenue growth.

Opex will be considered under a disciplined framework to support our sales initiatives, continue to improve cost leverage and deliver improved EBITDA performance and cashflow.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has recommended PolyNovo. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Earnings Results

A man and a woman sit in front of a laptop looking fascinated and captivated.
Financial Shares

5 ASX 200 financial stocks reporting next week

Earnings season is underway...

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Earnings Results

Why is this leading ASX 200 REIT under pressure on Friday?

Investors are pressuring the ASX 200 REIT on Friday. Let’s find out why.

Read more »

A happy young couple celebrate a win by jumping high above their new sofa.
Earnings Results

Nick Scali shares jump 12% on better than expected half year results

How did the furniture retailer perform during the first half? Here's what you need to know.

Read more »

Oil worker using a smartphone in front of an oil rig.
Earnings Results

ASX 200 energy stock tumbles despite 50% dividend boost

The ASX 200 energy stock is under heavy selling pressure on Thursday. But why?

Read more »

Earnings Results

This $27 billion ASX 200 share is jumping on strong quarterly results

Investors are cheering on this giant's quarterly update this morning.

Read more »

Business people discussing project on digital tablet.
Real Estate Shares

REA shares sink after CEO exit overshadows half-year profit beat

A strong result has been offset by news that the company's CEO is stepping down.

Read more »

Three smiling corporate people examine a model of a new building complex.
Earnings Results

2 ASX 300 real estate shares charging higher on half-year results

Did these shares deliver strong results? Let's find out.

Read more »

Woman on the phone at a hardware store.
Industrials Shares

Why this $18 billion ASX 200 stock is lifting off on Wednesday

The ASX 200 company is racing ahead of the benchmark.

Read more »